Pharmacogenetics in older people: What we know and what we need to know

Davide Seripa, Giulia Paroni, Maria Urbano, Stefano A. Santini, Grazia D'Onofrio, Alberto Pilotto

Research output: Contribution to journalArticle

Abstract

The prevalence of therapeutic failures (TFs) and adverse drug reactions (ADRs) markedly increased in older subjects. However, both TFs and ADRs did not always appear related to the presence of multiple pharmacologic treatments, a common status in subjects aged 65 and over. Instead, they seem more related to variations in the genes encoding protein metabolizing and transporting drugs. Thus, variations in these proteins may account for the inter-individual differences observed in drug efficacy, including the most severe clinical consequences TFs and ADRs. The genetics of drug metabolizing enzymes (DMEs) and drug transporters (DTs) is a very active area of multidisciplinary research, overlapping the fields of medicine, biology, pharmacology, and genetics. These proteins are virtually responsible for metabolism and disposition, and thus the efficacy, of a number of drugs currently used in clinical practice. This article explored some basic concepts of the pharmacogenetics of DMEs and DTs. We also focused current knowledge of the genetic basis of TFs and ADRs of the most common drugs currently used in geriatric clinics. The knowledge of what we know and what we need to know is needed to advance the application of pharmacogenetics in clinical practice, in order to introduce personalized treatments for elderly people.

Original languageEnglish
JournalJournal of Nephrology
Volume25
Issue numberSUPPL.19
DOIs
Publication statusPublished - 2012

Fingerprint

Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Therapeutics
Proteins
Enzymes
Individuality
Geriatrics
Medicine
Pharmacology
Research

Keywords

  • Adverse drug reaction
  • Drug metabolizing enzyme
  • Drug transporter
  • Elderly
  • Pharmacogenetics
  • Therapeutic failure

ASJC Scopus subject areas

  • Nephrology

Cite this

Pharmacogenetics in older people : What we know and what we need to know. / Seripa, Davide; Paroni, Giulia; Urbano, Maria; Santini, Stefano A.; D'Onofrio, Grazia; Pilotto, Alberto.

In: Journal of Nephrology, Vol. 25, No. SUPPL.19, 2012.

Research output: Contribution to journalArticle

Seripa, Davide ; Paroni, Giulia ; Urbano, Maria ; Santini, Stefano A. ; D'Onofrio, Grazia ; Pilotto, Alberto. / Pharmacogenetics in older people : What we know and what we need to know. In: Journal of Nephrology. 2012 ; Vol. 25, No. SUPPL.19.
@article{fc3ed37d52c347638c977175f301c825,
title = "Pharmacogenetics in older people: What we know and what we need to know",
abstract = "The prevalence of therapeutic failures (TFs) and adverse drug reactions (ADRs) markedly increased in older subjects. However, both TFs and ADRs did not always appear related to the presence of multiple pharmacologic treatments, a common status in subjects aged 65 and over. Instead, they seem more related to variations in the genes encoding protein metabolizing and transporting drugs. Thus, variations in these proteins may account for the inter-individual differences observed in drug efficacy, including the most severe clinical consequences TFs and ADRs. The genetics of drug metabolizing enzymes (DMEs) and drug transporters (DTs) is a very active area of multidisciplinary research, overlapping the fields of medicine, biology, pharmacology, and genetics. These proteins are virtually responsible for metabolism and disposition, and thus the efficacy, of a number of drugs currently used in clinical practice. This article explored some basic concepts of the pharmacogenetics of DMEs and DTs. We also focused current knowledge of the genetic basis of TFs and ADRs of the most common drugs currently used in geriatric clinics. The knowledge of what we know and what we need to know is needed to advance the application of pharmacogenetics in clinical practice, in order to introduce personalized treatments for elderly people.",
keywords = "Adverse drug reaction, Drug metabolizing enzyme, Drug transporter, Elderly, Pharmacogenetics, Therapeutic failure",
author = "Davide Seripa and Giulia Paroni and Maria Urbano and Santini, {Stefano A.} and Grazia D'Onofrio and Alberto Pilotto",
year = "2012",
doi = "10.5301/jn.5000137",
language = "English",
volume = "25",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Springer International Publishing",
number = "SUPPL.19",

}

TY - JOUR

T1 - Pharmacogenetics in older people

T2 - What we know and what we need to know

AU - Seripa, Davide

AU - Paroni, Giulia

AU - Urbano, Maria

AU - Santini, Stefano A.

AU - D'Onofrio, Grazia

AU - Pilotto, Alberto

PY - 2012

Y1 - 2012

N2 - The prevalence of therapeutic failures (TFs) and adverse drug reactions (ADRs) markedly increased in older subjects. However, both TFs and ADRs did not always appear related to the presence of multiple pharmacologic treatments, a common status in subjects aged 65 and over. Instead, they seem more related to variations in the genes encoding protein metabolizing and transporting drugs. Thus, variations in these proteins may account for the inter-individual differences observed in drug efficacy, including the most severe clinical consequences TFs and ADRs. The genetics of drug metabolizing enzymes (DMEs) and drug transporters (DTs) is a very active area of multidisciplinary research, overlapping the fields of medicine, biology, pharmacology, and genetics. These proteins are virtually responsible for metabolism and disposition, and thus the efficacy, of a number of drugs currently used in clinical practice. This article explored some basic concepts of the pharmacogenetics of DMEs and DTs. We also focused current knowledge of the genetic basis of TFs and ADRs of the most common drugs currently used in geriatric clinics. The knowledge of what we know and what we need to know is needed to advance the application of pharmacogenetics in clinical practice, in order to introduce personalized treatments for elderly people.

AB - The prevalence of therapeutic failures (TFs) and adverse drug reactions (ADRs) markedly increased in older subjects. However, both TFs and ADRs did not always appear related to the presence of multiple pharmacologic treatments, a common status in subjects aged 65 and over. Instead, they seem more related to variations in the genes encoding protein metabolizing and transporting drugs. Thus, variations in these proteins may account for the inter-individual differences observed in drug efficacy, including the most severe clinical consequences TFs and ADRs. The genetics of drug metabolizing enzymes (DMEs) and drug transporters (DTs) is a very active area of multidisciplinary research, overlapping the fields of medicine, biology, pharmacology, and genetics. These proteins are virtually responsible for metabolism and disposition, and thus the efficacy, of a number of drugs currently used in clinical practice. This article explored some basic concepts of the pharmacogenetics of DMEs and DTs. We also focused current knowledge of the genetic basis of TFs and ADRs of the most common drugs currently used in geriatric clinics. The knowledge of what we know and what we need to know is needed to advance the application of pharmacogenetics in clinical practice, in order to introduce personalized treatments for elderly people.

KW - Adverse drug reaction

KW - Drug metabolizing enzyme

KW - Drug transporter

KW - Elderly

KW - Pharmacogenetics

KW - Therapeutic failure

UR - http://www.scopus.com/inward/record.url?scp=84872047801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872047801&partnerID=8YFLogxK

U2 - 10.5301/jn.5000137

DO - 10.5301/jn.5000137

M3 - Article

C2 - 22476963

AN - SCOPUS:84872047801

VL - 25

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - SUPPL.19

ER -